Table 3 Clinicopathological characterestics of patients with breast cancer.

From: Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk

 

n = 162

%F

(N +)

Tumor type

Infiltrative ductal carcinoma (IDC)

68.5

(111)

Medullary carcinoma

3.7

(6)

Metaplastic carcinoma

2.5

(4)

Mucinous carcinoma

0.6

(1)

Lobular carcinoma

2.5

(4)

Phyllodes tumor

1.9

(3)

Ductal carcinoma in situ (DCIC)

1.2

(2)

Unknown

19.1

(31)

Tumor side

Left

37

(60)

Right

34.6

(56)

Bilateral

1.2

(2)

Unknown

27.2

(44)

Histological tumor grade

I—Well differentiated

14.8

(24)

II—Moderately differentiated

41.4

(67)

III—Poorly differentiated

9.3

(15)

Unknown

34.6

(56)

Lymph node involvement

Positive

44.4

(72)

Negative

30.9

(50)

Unknown

24.7

(40)

TNM staging

I

6.8

(11)

II

36.4

(59)

III

25.9

(42)

IV

1.2

(2)

Unknown

29.6

(48)